Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: OTCMKTS:TTNP
- CUSIP: N/A
- Web: www.titanpharm.com/
- Market Cap: $41.35 million
- Outstanding Shares: 21,203,000
- 50 Day Moving Avg: $2.11
- 200 Day Moving Avg: $3.06
- 52 Week Range: $1.75 - $6.40
Sales & Book Value:
- Trailing P/E Ratio: 15.48
- Foreward P/E Ratio: -4.88
- P/E Growth: 0.00
- Annual Revenue: $15.1 million
- Price / Sales: 2.74
- Book Value: $0.50 per share
- Price / Book: 3.90
- EBIDTA: $3.12 million
- Net Margins: -7,512.50%
- Return on Equity: -101.29%
- Return on Assets: -75.95%
- Average Volume: 153,913 shs.
- Short Ratio: 4.94
Frequently Asked Questions for Titan Pharmaceuticals (OTCMKTS:TTNP)
What is Titan Pharmaceuticals' stock symbol?
Titan Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TTNP."
How were Titan Pharmaceuticals' earnings last quarter?
Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) released its earnings results on Wednesday, May, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. Titan Pharmaceuticals had a negative net margin of 7,512.50% and a negative return on equity of 101.29%. View Titan Pharmaceuticals' Earnings History.
Where is Titan Pharmaceuticals' stock going? Where will Titan Pharmaceuticals' stock price be in 2017?
1 analysts have issued 1-year price targets for Titan Pharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Titan Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Titan Pharmaceuticals.
Who are some of Titan Pharmaceuticals' key competitors?
Some companies that are related to Titan Pharmaceuticals include KalVista Pharmaceuticals (KALV), Cesca Therapeutics (KOOL), Chiasma (CHMA), Mirna Therapeutics (MIRN), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA), Onconova Therapeutics (ONTX), Catalyst Biosciences (CBIO), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX), Ocera Therapeutics (TZYM), Transition Therapeutics (TTHI) and Vitae Pharmaceuticals (VTAE).
Who are Titan Pharmaceuticals' key executives?
Titan Pharmaceuticals' management team includes the folowing people:
- Marc Rubin M.D., Executive Chairman of the Board
- Sunil Ramraje Bhonsle, President, Director
- Rajinder Kumar, Director
- Scott A. Smith, Director
- Joseph A. Akers, Independent Director
- Eurelio M. Cavalier, Independent Director
- M. David David MacFarlane Ph.D., Independent Director
Who owns Titan Pharmaceuticals stock?
Titan Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Municipal Employees Retirement System of Michigan (1.43%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Joseph A Akers, Marc Rubin and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals.
Who bought Titan Pharmaceuticals stock? Who is buying Titan Pharmaceuticals stock?
Titan Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Joseph A Akers, Marc Rubin and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals.
How do I buy Titan Pharmaceuticals stock?
Shares of Titan Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Titan Pharmaceuticals' stock price today?
MarketBeat Community Rating for Titan Pharmaceuticals (OTCMKTS TTNP)MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Titan Pharmaceuticals stock can currently be purchased for approximately $1.95.
Consensus Ratings for Titan Pharmaceuticals (OTCMKTS:TTNP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.00|
Analysts' Ratings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
(Data available from 7/27/2015 forward)
|3/20/2017||Roth Capital||Set Price Target||Buy||$10.00|
Earnings History for Titan Pharmaceuticals (OTCMKTS:TTNP)Earnings History by Quarter for Titan Pharmaceuticals (OTCMKTS TTNP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 2017||($0.15)||($0.16)||$0.09 million||$0.04 million||View||N/A|
|11/9/2016||Q316||($0.11)||($0.12)||$0.25 million||$0.03 million||View||Listen|
|8/13/2015||($0.02)||($0.02)||$0.86 million||$0.76 million||View||N/A|
|5/13/2015||($0.03)||($0.04)||$0.66 million||$0.91 million||View||N/A|
|3/31/2015||($0.01)||($0.01)||$0.91 million||$0.91 million||View||N/A|
|11/13/2014||($0.02)||($0.01)||$0.90 million||$0.91 million||View||N/A|
|8/13/2014||($0.02)||($0.01)||$0.90 million||$0.91 million||View||N/A|
Earnings Estimates for Titan Pharmaceuticals (OTCMKTS:TTNP)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.40 EPS
Dividend History for Titan Pharmaceuticals (OTCMKTS:TTNP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Titan Pharmaceuticals (OTCMKTS:TTNP)Insider Trades by Quarter for Titan Pharmaceuticals (OTCMKTS:TTNP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/19/2016||Joseph A Akers||Director||Buy||13,000||$4.85||$63,050.00|| |
|7/18/2016||Sunil Bhonsle||CEO||Buy||10,000||$4.96||$49,600.00|| |
|5/31/2016||James R Mcnab||Director||Buy||20,000||$7.03||$140,600.00|| |
|2/22/2016||Sunil Bhonsle||CEO||Buy||11,763||$3.56||$41,876.28|| |
|1/15/2016||Sunil Bhonsle||CEO||Buy||5,841||$2.72||$15,887.52|| |
|1/13/2016||James R Mcnab||Director||Buy||16,363||$3.16||$51,707.08|| |
|1/11/2016||Marc Rubin||Chairman||Buy||5,000||$3.25||$16,250.00|| |
|1/11/2016||Sunil Bhonsle||CEO||Buy||17,000||$3.18||$54,060.00|| |
|9/16/2015||Sunil Bhonsle||President||Buy||10,000||$0.70||$7,000.00|| |
|8/28/2015||Marc Rubin||Chairman||Buy||50,000||$0.72||$36,000.00|| |
|8/25/2015||Sunil Bhonsle||President||Buy||50,000||$0.70||$35,000.00|| |
Headline Trends for Titan Pharmaceuticals (OTCMKTS:TTNP)
Latest Headlines for Titan Pharmaceuticals (OTCMKTS:TTNP)
|Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants|
finance.yahoo.com - July 6 at 2:43 PM
|Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology|
finance.yahoo.com - June 29 at 7:36 AM
|TTNP: First Quarter Results; Development Programs on Track.|
finance.yahoo.com - May 16 at 8:34 PM
|Titan Pharmaceuticals, Inc. (TTNP) Releases Earnings Results, Misses Expectations By $0.01 EPS|
www.americanbankingnews.com - May 11 at 2:46 PM
|Edited Transcript of TTNP earnings conference call or presentation 10-May-17 8:15pm GMT|
finance.yahoo.com - May 11 at 9:23 AM
|Titan Pharmaceuticals Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 10 at 10:11 AM
|ETFs with exposure to Titan Pharmaceuticals, Inc. : May 5, 2017|
finance.yahoo.com - May 5 at 11:42 PM
|Titan Pharmaceuticals Schedules Conference Call To Review First Quarter 2017 Financial Results|
finance.yahoo.com - May 4 at 10:07 AM
|Titan Pharmaceuticals (TTNP) Earns Daily News Impact Rating of 0.23|
www.americanbankingnews.com - April 24 at 6:51 PM
|Titan Pharmaceuticals (TTNP) Receives Media Sentiment Score of 0.16|
www.americanbankingnews.com - April 21 at 9:40 PM
|ETFs with exposure to Titan Pharmaceuticals, Inc. : April 20, 2017|
finance.yahoo.com - April 20 at 11:06 PM
|TTNP: 2016 Results; Deep Dive on Development Programs|
finance.yahoo.com - March 27 at 7:34 PM
|Titan Pharmaceuticals, Inc. (TTNP) PT Set at $10.00 by Roth Capital|
www.americanbankingnews.com - March 24 at 7:32 AM
|Titan Pharmaceuticals Reports Full Year And Fourth Quarter 2016 Financial Results|
us.rd.yahoo.com - March 17 at 3:42 AM
|Q4 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not Supplied|
us.rd.yahoo.com - March 17 at 3:42 AM
|TITAN PHARMACEUTICALS INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 17 at 3:42 AM
|Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results|
us.rd.yahoo.com - March 11 at 9:42 PM
|Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results - Yahoo Finance|
finance.yahoo.com - March 11 at 8:28 AM
|Titan Pharmaceuticals To Present At 29th Annual ROTH Conference|
finance.yahoo.com - March 7 at 8:35 AM
|Titan Pharmaceuticals Receives FDA Communication On Ropinirole Implant Investigational New Drug Application|
us.rd.yahoo.com - February 28 at 11:22 AM
|TITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events|
biz.yahoo.com - February 27 at 8:45 AM
|Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech|
finance.yahoo.com - February 14 at 6:41 AM
|Market Analysis: Titan's Probuphine Faces Challenges Ahead - Seeking Alpha|
seekingalpha.com - February 8 at 8:07 AM
|Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services|
us.rd.yahoo.com - January 14 at 6:41 AM
|8:09 am Titan Pharma announces that the Centers for Medicare & Medicaid Services has granted a permanent J-code for Probuphine for the maintenance treatment of opioid addiction; the new J-code became effective January 1, 2017|
us.rd.yahoo.com - January 14 at 6:41 AM
|TITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - January 10 at 2:56 AM
|TITAN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh|
biz.yahoo.com - January 5 at 7:17 AM
|Titan Pharmaceuticals Appoints Two New Board Members|
finance.yahoo.com - January 4 at 7:16 AM
|10 Pharmaceuticals Stocks to Sell Now - Investorplace.com|
investorplace.com - December 24 at 3:11 AM
|TTNP: Training Providers and Securing Payors; 3Q:16 Results|
finance.yahoo.com - November 21 at 8:34 PM
|Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year|
finance.yahoo.com - November 21 at 8:34 PM
Titan Pharmaceuticals (TTNP) Chart for Thursday, July, 27, 2017